We're proud to add Alpha Cognition, Inc. (CNSX: $ACOG) to the roster of quality presenting companies at the upcoming B2i Digital Featured Conference: Spartan Capital Securities, LLC Investor Conference 2024. The event is scheduled for November 4th at The Pierre Hotel in New York City. Alpha Cognition, Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative disease, such as Alzheimer’s disease and Cognitive Impairment with mild Tramautic Brain Injury (“mTBI”). The Company’s first product ZUNVEYL is approved by the U.S. Food and Drug Administration (FDA) as a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Alpha Cognition, Inc. initiatives are spearheaded by Denis Kay, Phillip Mertz, Michael Mcfadden, and Don Kalkofen. Conference attendees will have the unique opportunity to engage directly with Alpha Cognition, Inc. executives, gaining valuable insights into the company’s development in novel treatments for under-served neurodegenerative diseases. The Spartan Capital Investor Conference brings together an impressive array of public company executives, institutional investors, and thought leaders in the U.S. capital markets. With over 30 companies slated to present, the event promises unparalleled networking opportunities. For those interested in attending this exclusive event, please submit a request to participate at https://lnkd.in/e6ZQhZyA Kindly note that attendance is limited and subject to approval. Thank you to our hosts at Spartan Capital who made this event possible: John D. Lowry, Kim Monchik, Joe Giamichael, Stephen Faucetta, Julia Voss, William Birney, Donald Powell, Louis Valdez, Abdiell (AJ) Suero, Blake Weltmann, Ralph Metz and many others. Spartan Capital Securities, LLC is a full-service, integrated financial services firm trusted by high-net-worth individuals and institutions for sound investment guidance. We focus on understanding our clients' objectives and executing strategies to meet their financial goals. #SpartanCapital #B2iDigital #InvestorConference #CapitalMarkets #InstitutionalInvestors #SpartanCapitalInvestorConference2024 #AlphaCognition #ACOG #biopharmaceutical
David Shapiro’s Post
More Relevant Posts
-
💊 Navigating the Future of Biopharma: 2025 JP Morgan Healthcare Conference Insights 💊 The upcoming 2025 JP Morgan Healthcare Conference is set to highlight transformative catalysts in the biopharma industry. Here’s what’s on the radar: 🔬 Innovation Pipeline: A focus on groundbreaking therapies in oncology, gene therapy, and rare diseases. 📈 Strategic Investments: Companies will emphasize partnerships, M&A, and funding to advance innovation. 🌍 Global Market Dynamics: Discussions on navigating regulatory landscapes, pricing pressures, and sustainability goals. For those of us in pharma marketing, this conference serves as a bellwether for industry trends. Staying attuned to these developments helps us craft impactful communication strategies that resonate with both stakeholders and patients. Read more at https://lnkd.in/eTKBRxAW #Biopharma #Innovation #JPMS2025 #HealthcareMarketing #FutureOfMedicine
To view or add a comment, sign in
-
How Will Europe Use its Vast Biomedical Data to Power Drug Finding and Drug Development? Hear from Rowan Gardner, Chief Business & Investment Officer and Co-founder of PrecisionLife, at Bio€quity Europe - https://lnkd.in/eFhYhEpN. Rowan will share her thoughts panel the panel session at 1:30PM on 14 May alongside Selina Koch, PhD, Head of Intelligence & Research at BioCentury Inc., Emmanuelle Astoul, Interim Head of Translation at Wellcome Sanger Institute, Nick Lench, Executive Director of NATA - Nucleic Acid Therapy Accelerator, and Miriam Rodríguez González, CEO of Savana. ● Learn about our unique ability to identify the causal biology in complex diseases and link patients to effective treatments via mechanism-based biomarkers of their disease and/or drug response. ● Schedule a meeting with Rowan in the one-to-one partnering system and discover out how PrecisionLife de-risks, accelerates, and maximize success at every stage of biopharma, diagnostics, and healthcare innovation for patients with unmet medical needs. More information is available here: https://lnkd.in/eFhYhEpN Thanks to BioCentury Inc. and EBD Group for organizing what promises to be another outstanding event. #PrecisionMedicine #Biopharma #Biotech #Techbio #VentureCapital #DrugDevelopment #BiopharmaInnovation
Hear from and partner with Rowan Gardner at Bio€quity
precisionlife.com
To view or add a comment, sign in
-
With #BIO2024 taking place this week in San Diego, the life sciences community closes in on a mid-year check-in point. A time when thousands of the greatest scientific innovators from across the globe come together to take a pulse on the state of the industry, reflect on the first half of the year and predict what lies ahead. As the life sciences community comes together and looks ahead to what's needed to accelerate the development and delivery of modern therapeutics, they must move beyond traditional research spaces and large-scale manufacturing and global distribution centers. In my recent interview with @BioPharmaDive, I discuss how SmartLabs is helping to bridge the gap between traditional and modern drug development through our first-in-class, integrated offerings which combine reconfigurable lab infrastructure, operations, and scientific expertise. Read the full Q&A on BioPharmDive: https://lnkd.in/g_iYzUXe #SmartLabs #EnablingTheFutureOfScience #BioPharma #LabSolutions
Thinking inside the box: How SmartLabs is supporting the science of tomorrow
biopharmadive.com
To view or add a comment, sign in
-
Testimonial Time 🕒💬 We are thrilled to share a glowing testimonial from Alexander Brand, Associate Director of Business Development at Burning Rock Dx about his experience at our recent hubXchange event. Alex shares how a hubXchange event has plenty of networking breaks, emphasising how this smaller format is more manageable to navigate, compared to larger events and conferences, resulting in more meaningful connections, ultimately resulting in good value prospects and leads. hubXchange is all about creating a platform where professionals like Alexander can connect, collaborate, and drive forward the future of healthcare. Whether you're looking to build strategic partnerships or gain fresh perspectives, our events provide the ideal environment to do just that. Don't miss out on our next event series' Experience first-hand why leaders in the industry are choosing hubXchange as their go-to platform for innovation and growth. 🚀 San Francisco - LIMITED PLACES REMAIN!⚠️🚨 🟡 Antibody Therapeutics Xchange - https://lnkd.in/e_Du_ArY 🟣 Immuno-Oncology Xchange - https://lnkd.in/eFYKvNfK 🟢 Advanced Therapies Xchange - https://lnkd.in/eWzTsXzb 🔵 AI in Drug Discovery Xchange - https://lnkd.in/e9Ve2Fef Maryland 🟡 Antibody Therapeutics Xchange - https://lnkd.in/e_rpSrm6 🟣 Immunotherapies Xchange - https://lnkd.in/eKUAPRw2 🟠 Oligonucleotide Xchange - https://lnkd.in/ep67ue6R 🔵 AI in Drug Discovery Xchange - https://lnkd.in/eJKYrtTH #lifescience #ScientificDiscussion #Roundtable #roundtabletalk #roundtablemeeting #roundtablediscussion #Lifescienceevent #hubXchange #Testimonial #RavingReviews #Innovation #Collaboration #hubXchange #LifeSciences
To view or add a comment, sign in
-
As 2024 draws to a close, it’s great to reflect on the progress we’ve made at OMass. It’s been a year of growth, innovation and impactful progress, bringing us closer towards our mission of bringing transformative medicines to patients in need. The key highlights of OMass’ 2024 include: · The nomination of our first clinical candidate targeting the melanocortin-2 (MC2) receptor · Strengthening and expanding our team with the appointments of Dr. Steven Griffen as VP of Clinical Development, Angela Hecyk as Director of Clinical Operations, Stuart Hadley as Senior Director of CMC and Dr. Sarah Teichmann FMedSci FRS to our SAB, as well as the promotions of Dr. Hsin Loke to COO, Dr. Jon Roffey to SVP of Discovery and Non-Clinical and Professor Steven Charlton to CSO · Being named one of Fierce Biotech’s “Fierce 15” biotechnology companies for 2024 Looking ahead, we are poised for an exciting 2025. With our MC2 receptor antagonist set to enter IND-enabling studies, we continue to advance our immunology and rare disease portfolios, and our pipeline is stronger than ever. Our goal is clear: to build a fully integrated biopharma company that brings life changing medicines to market. Read the full blog here: https://lnkd.in/evdUGhye #festive #drugdiscovery #masspec #biotech #LifeScience #innovation
To view or add a comment, sign in
-
-
Our SPATIALPlex Solutions bring innovative approaches to your biomarker and clinical development programs. Spatially visualizing drug activity with unparalleled precision, Flagship Biosciences supports discovery and target engagement decisions that transcend conventional approaches and enable vivid insights to refine drug efficacy. Learn more… https://hubs.la/Q02rq17H0 #SpatialBiology #SpatialPlexSolutions #DigitalPathology #DrugDevelopment
To view or add a comment, sign in
-
-
We’re pleased to share that Tom Equels, CEO of our B2i Digital Featured Company AIM ImmunoTech (NYSE American: $AIM) https://lnkd.in/erRzxGa9, will participate in the Virtual Investor Pitch Conference on Monday, June 17, 2024, at 1:00 PM ET. During the event, Mr. Equels will provide corporate overview, business outlook, and outline the Company’s upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participants can submit questions live during the event, and Equels will answer as many as possible in the allotted time. - Register for the live video webcast here: https://lnkd.in/etYzuw_b - The presentation will also be available on the Events page of AIM’s website https://lnkd.in/g-cc2H5f, with a webcast replay accessible for 90 days following the event. - To view a copy of the press release, click here: https://lnkd.in/eh-nvJfi We look forward to this opportunity to hear directly from CEO Thomas Equels. In addition to Equels, AIM is led by a seasoned and accomplished leadership team, including COO Peter Rodino III, CMO David Strayer, Chris McAleer PhD PhD, and CFO Robert Dickey. If you have any investor-related questions about the company, please contact AIM’s investor relations team, Jenene Thomas, and her colleagues at JTC IR. #Biotech #ClinicalTrials #Manufacturing #Ampligen #B2iDigital #AIMImmunoTech #ImmunoOncology #PancreaticCancer #immunotherapy #Ampligen #InvestorConference
To view or add a comment, sign in
-
-
📰 | #NewsPCUV A historic step in the fight against myotonic dystrophy type 1! 🚀 #ARTHEx Biotech, a biotech spin-off of #UV, has administered the experimental drug #ATX01 to the first participant in a clinical trial. This breakthrough brings us closer to establishing a pioneering therapy for #DM1, a rare, devastating, and untreated disease that affects more than one million people worldwide. The #ArthemiR™ clinical trial, supported by the #EIC program, will evaluate the safety, tolerability, and efficacy of #ATX01 in 56 patients. If successful, this treatment could become the first effective drug for those facing this complex disease. Read the full story ⬇️ https://lnkd.in/dmxAD_7A Universitat de València | Generalitat Valenciana | ARTHEx Biotech | Ruben Artero | beatriz llamusi | Frederic LEGROS | European Innovation Council applicant support
ARTHEX Biotech begins clinical phase to test the efficacy of its drug for the treatment of myotonic dystrophy type 1
To view or add a comment, sign in
-
Excited to highlight an article featuring the groundbreaking work of our portfolio company, Kanso Diagnostics. Kanso is revolutionizing at-home medical diagnostics with their molecular testing platform, enabling rapid and accurate detection of multiple pathogens and genetic biomarkers from a single sample. This innovation reduces diagnosis time from days to minutes, offering PCR-grade accuracy and convenience for users. Together with fellow investors Israel Innovation Authority, BD and Bristol Myers Squibb, we are proud to see Kanso accelerating its mission to make diagnostics accessible anytime, anywhere, and to anyone. Discover more about Kanso's transformative approach in the full article: https://lnkd.in/dtFe7H8z It’s been a privilege to support Kanso on their journey to revolutionize at-home healthcare diagnostics. This innovation reflects the true spirit of advancing patient care and improving lives worldwide. #HealthTech #Innovation #LifeSciences
To view or add a comment, sign in
-
𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬, 𝐆𝐫𝐨𝐰𝐭𝐡, 𝐚𝐧𝐝 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 In this video, we dive into the fascinating world of the 𝐂𝐚𝐧𝐜𝐞𝐫 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭, exploring groundbreaking advancements, emerging technologies, and the global impact of these life-changing innovations. 𝐔𝐧𝐥𝐨𝐜𝐤 𝐚 𝐅𝐑𝐄𝐄 𝐒𝐚𝐦𝐩𝐥𝐞: https://lnkd.in/gxtXVRWC 𝐓𝐨𝐩𝐢𝐜𝐬 𝐂𝐨𝐯𝐞𝐫𝐞𝐝: · Key players and emerging companies. · Market size, growth trends, and future projections. · Challenges and opportunities in the cancer vaccine space. · The role of research and government funding. 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐑𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/gCcPeJQi Stay tuned to learn how science and technology are shaping the future of cancer treatment and prevention. Don’t forget to like, comment, and subscribe for more insights into the healthcare and pharmaceutical industries! 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞 𝐭𝐨 𝐎𝐮𝐫 𝐂𝐡𝐚𝐧𝐧𝐞𝐥: https://lnkd.in/gcKcHgRs #cancerdrug #healthcareinnovation #medicalbreakthroughs #cancerresearch #pharmamarket #marketresearch #markettrends #businessinsights
To view or add a comment, sign in
Co-Founder & Chief Scientific Officer at Alpha Cognition Inc.
4moGreat opportunity!